Axert has been approved by the FDA for the acute treatment of migraine with or without aura in adults.
Axert belongs to a class of drugs known as selective serotonin receptor agonists.Axert tablets contain almotriptan malate, a selective 5-hydroxytryptamine receptor agonist.
This drug targets serotonin receptors and act against migraine headaches by inducing the constriction of blood vessels surrounding the brain.
Nausea, sleepiness, numbness, dry mouth and headache are the side effects associated with the use of Axert. In controlled trials, Axert showed a low percentage of side effects.
However this class of compounds has the potential to cause coronary vasospasm, and as a result Axert is not advised for patients with ischemic or vasospastic artery disease.
This drug is introduced by the pharmaceutical company, Pharmacia. Results of controlled clinical trials demonstrated that Axert was highly effective and well tolerated.
Axert is now an exciting new migraine therapy from Pharmacia, proven effective in the acute treatment of migraine.